Purpose To describe the level of co-morbidity in patients with sight-threatening diabetic retinopathy in the United Kingdom.
Materials and methods
This study was undertaken in conjunction with a national study throughout the UK examining photocoagulation treatment for diabetic retinopathy, the full methodology of which has been described elsewhereY Patients eligible for inclusion in the study were those undergoing first laser treatment for diabetic maculopathy or proliferative retinopathy during a 2 month period throughout the UK. Questionnaires were completed by the ophthalmologist performing the laser treatment and by the patient prior to the initial laser treatment and at 9 month follow-up.
Disease (9) Younger-onset disease: diabetes diagnosed under age 30 years and on insulin treatment; older-onset disease: diabetes diagnosed after age 30 years, or not on insulin treatment.
Results
Eight hundred and thirty patients were recruited into the study overall. Of these 546 (65.8%) were undergoing their first laser treatment for maculopathy (in the absence of proliferative retinopathy) and 34.2% were undergoing their first panretinal photocoagulation in the affected eye.
A validation study showed that this represented 75.4% of all eligible patients,u Questionnaires were returned from 639 patients (76.9% of the patients recruited into the survey). There was no significant difference in the age
, visual acuity in the better eye (p = 0.3, Mann-Whitney U) or type of retinopathy (chi-squared 0.0009, p = 0.97) between the responders and the non responders to the patient questionnaire. Table 1 shows the demographic features for these patients. The mean age of the patients was 59.9 years (range 17-94 years). Diabetes was diagnosed under the age of 30 years and required insulin treatment in 15.5% of patients. Table 2 shows the self-reported general health for these patients undergoing first laser treatment for diabetic retinopathy.
Overall, 15% reported having angina, 8.8% had suffered a myocardial infarction, 5.9% had had a stroke and 8.5%
reported having known renal disease. compared with maculopathy (OR = 2.9, P < 0.01) and increased duration of diabetes (p = 0.03), but not independently related to the age or gender of the patient, or the type of diabetes. Symptoms of peripheral neuropathy were not found to be significantly associated with any of the factors included in the analysis. The presence of treated hypertension was significantly related to older-onset diabetes (OR = 4.9, P < 0.001), the duration of diabetes (p = 0.01) and female sex (OR = 1.6, P = 0.01), but not independently to the age of the patient or the type of retinopathy present. Previous cataract surgery had been performed in 11.7% of patients.
No association was found between the outcome of treatment for proliferative retinopathy or maculopathy between those patients with or without self-reported ischaemic heart disease, cerebrovascular disease, renal disease, treated hypertension or smoking history, in terms of either visual acuity or morphological outcome.
Patients were asked how many times they had visited a variety of health care workers in the previous year. The total number of visits to any health care worker in the previous year was a mean 15.6 (range 1-188, SD 14.5). One hundred and twelve patients (17.5%) had been admitted to hospital in the previous 6 months (median 0 times, range 0-22 for all cases). The number of nights as an inpatient in the previous 6 months was a mean 2.6 (range 0-112).
Overall 56.3% (360) of respondents said that they had been smokers at some stage in their lives and 12.2% (78) of respondents said that they were still smoking. For those who had stopped smoking, 57.2% had stopped prior to the diagnosis of diabetes whilst 42.8% had stopped after the diagnosis was made. For those who were still smoking the mean number of cigarettes smoked per day was 12.6 (range 2-35), whilst for those who had previously been smokers, the mean number of cigarettes was 19.9 (range 1-100). In response to the question about the patients' understanding of the risk of smoking to their health, 56.1% (330) responded that they thought the risk to their health from smoking was greater because they were diabetic, 17.7% (104) said that they thought the risk to their health from smoking was the same as for someone who was not diabetic, 0.5% (3) felt that the risk to their health was less and 25.7% (151) said that they did not know. For the group who were still smoking, 42.3% (33) said that they were aware that the risk to their health was greater because they were diabetic, and 28.2% (22) said that they did not know.
Discussion
This study highlights the high prevalence of co morbidity in this group of patients with sight-threatening diabetic retinopathy. Overall 28% described angina, myocardial infarction, transient ischaemic attack or stroke, and this was 12% for the group of patients aged less than 65 years. The presence of ischaemic heart disease or cerebrovascular disease was found to be associated with increasing age and increasing duration of diabetes, but not with the gender of the patient. The prevalence of macrovascular complications in diabetic patients has been shown to be increased 2-to 3-fold in men and 4-to 5-fold in premenopausal women, and the fact that the presence of macrovascular complications in this study was not related to the gender of the patient highlights the fact that diabetes abolishes the protective effect of being female.12 , 13 Renal disease was reported by 8.5% of patients overall and in 14% of patients with proliferative retinopathy. The presence of renal disease was found to be associated with proliferative retinopathy rather than maculopathy and with increased duration of diabetes. These self-reported figures will certainly be an underestimate of the number of patients with any degree of nephropathy. Although the incidence of nephropathy is thought to be declining, particularly for type I diabetes, it is thought that renal disease will develop in 20-25% of patients with diabetes.14 Twenty-four per cent of patients were aware of numbness in their feet, 10.5% had suffered foot ulceration and 4.4% had undergone amputation of all or part of a limb. A community survey found a prevalence of neuropathy of 16% compared with 3% in the non diabetic population, and that past or present foot ulceration was present in 7.4% in people with diabetes compared with 2.5% in the control group.1 5, 1 6 The
Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) found a prevalence of foot ulceration in 9.5% of the younger-onset group of patients with diabetes, and 10.5% of the older-onset group. The 4 year incidence of lower-limb amputation was 2.2% overal1.17
Higher rates of co-morbidity would be expected in our survey, since these patients had more severe degrees of retinopathy than a community sample of patients with diabetes and might thus be expected to have higher levels of other diabetes-related complications.
Nabarro reported a series of 6780 patients with diabetes mellitus, of whom 20.8% had type I diabetes.18 This was a highly selected group of patients who were seen in a hospital diabetes clinic between 1954 and 1988.
He found clinically important neuropathy in 17.4% of patients with type I diabetes and in 11.6% of those with type II diabetes. Foot ulceration occurred in 5.7% of patients, and major amputations were needed in 1.2% of patients. Coronary artery disease was found in 9% of patients with type I diabetes, and was as common in women as men.
In the Diabetic Retinopathy Study (DRS) at recruitment, 10.2% reported having kidney disease, 4.8% had suffered a myocardial infarction, 2.7% had had a stroke and 3.4% had had an amputation? However, one of the eligibility criteria for the DRS was that 'the outlook for survival and availability for 5 years of follow-up was judged good by the examining physician' and patients over 70 years were not eligible. It is therefore not surprising that the levels of co-morbidity are higher in our group of patients with proliferative retinopathy.
Two hundred and twenty-seven of the patients in our study (35.5%) reported being on treatment for hypertension, and this was related to the duration of diabetes, older-onset diabetes and female gender. These figures are in accord with other studies. A population study from the USA showed that 41 % of the patients with diabetes were on treatment for hypertension compared with 22.4% of the controls. 19 Among patients with diabetes on oral hypoglycaemic agents, 52.9% of the women were on treatment for hypertension compared with 39% of the men. In the DRS 29.3% of patients were on antihypertensive treatment at baseline, and this was more common in women than men (37.4% vs 22.8%).
The prevalence of current smoking of 12.2% for the patients in this survey can be compared with a national American survey in 1989 which showed that 27% of people with diabetes reported currently smoking cigarettes?O In the DRS at baseline 32.4% of patients were current cigarette smokers and 20.1% were former smokers? The levels of current smoking in our survey compare favourably with these other studies. However, it is of note that only 56.1 % of patients (and 42.3% of smokers) were aware that smoking was a greater risk to their health because they had diabetes. This would suggest the need for better education about the risks of smoking for these patients. This study found no association between the systemic health of these patients and the outcome of photocoagulation treatment. However, the study was not specifically designed to address this issue, self-reporting is likely to underestimate the level of disease (especially renal) and the group on treatment for hypertension may well not have significantly different levels of blood pressure compared with the group not requiring treatment.
In conclusion, this study highlights the high prevalence of co-morbidity in patients undergoing laser treatment for diabetic retinopathy in the UK. This may affect the treatment of their retinopathy, as the patients may be frequently hospitalised or unwell, causing them to miss or postpone their appointments, and may alter the threshold for panretinal photocoagulation treatment if careful follow-up cannot be maintained?1,22 Moreover, poor systemic health may exacerbate diabetic macular oedema, and control of systemic factors rather than laser treatment may be a necessary initial treatment option. It is therefore very important to be aware of the systemic status of diabetic patients with retinopathy, since this may affect their management. This study details the prevalence of associated disease in patients undergoing laser treatment for diabetic retinopathy.
